Pharma Focus Europe

Valo Therapeutics and Texcell Announce Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study

Wednesday, June 14, 2023

Valo Therapeutics Oy (ValoTx), a company specializing in the development of adaptable immunotherapies for cancer, has announced a collaboration with Texcell, a global contract research organization. The partnership aims to investigate the immune responses generated by PeptiCRAd-1 in a Phase I clinical study.

PeptiCRAd-1, developed by ValoTx, combines a tumor-specific adenovirus expressing immune-stimulatory molecules CD40L and OX40L with immunogenic tumor peptides derived from NY-ESO-1 and MAGE-A3 proteins. This unique combination is designed to activate cytotoxic T-cells that specifically target and eliminate cancer cells.

The Phase I clinical study, an open-label and non-randomized trial, will involve up to 15 patients across multiple cancer types. Its primary objectives are to assess the safety of PeptiCRAd-1 in combination with the checkpoint inhibitor pembrolizumab, explore the therapy's immunological mechanism of action, and gather preliminary data on its clinical activity. By collaborating with Texcell, ValoTx aims to gain insights into the immunological response elicited by PeptiCRAd-1 and the mechanism of action of VALO-D102, their oncolytic adenovirus.

Dr. Sari Pesonen, Chief Scientific Officer at ValoTx, expressed enthusiasm about the collaboration, emphasizing the opportunity to unlock the anti-tumor potential of VALO-D102 by directing immune responses toward tumor-specific antigens. This collaboration will contribute to the ongoing efforts of reinventing immunotherapy to make it more effective.

Dr. François Nicolas, Chief Business Officer at Texcell, expressed satisfaction with the collaboration, citing their 30 years of expertise in immunology. Both ValoTx and Texcell are optimistic about the impact this partnership will have on the medical industry and, more importantly, on cancer patients.

This collaboration between Valo Therapeutics and Texcell marks an important step in evaluating the immune responses to PeptiCRAd-1 and advancing the development of innovative immunotherapies for cancer treatment.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva